Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight into the Early Response to Sclerostin Antibody in Rats

Journal of Bone and Mineral Research

Volumn 30, Issue 8, 2015, Pages 1457-1467

  Nioi, Paul ^a   Taylor, Scott ^a   Hu, Rong ^a   Pacheco, Efrain ^a   He, Yudong D ^a   Hamadeh, Hisham ^a   Paszty, Chris ^a   Pyrah, Ian ^a   Ominsky, Michael S ^a   Boyce, Rogely Waite ^a  

^a AMGEN INC   (United States)

Author keywords

ANABOLICS; MOLECULAR PATHWAYS; OSTEOPOROSIS; SCLEROSTIN ANTIBODIES; TRANSCRIPTION FACTORS; WNT b CATENIN LRPs

Indexed keywords

ANTIBODY; MESSENGER RNA; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MATRIX; CELL CYCLE ARREST; CELL LINEAGE; GENE; GENE EXPRESSION; LASER CAPTURE MICRODISSECTION; LUMBAR VERTEBRA; MICROARRAY ANALYSIS; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OVARIECTOMY; RAT; TWIST1 GENE; UPREGULATION; WISP1 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC TRANSCRIPTION; LASER; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; WNT SIGNALING PATHWAY;

ANIMALS; ANTIBODIES; BONE MORPHOGENETIC PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; LASERS; LUMBAR VERTEBRAE; OSTEOBLASTS; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION, GENETIC; WNT SIGNALING PATHWAY;

EID: 84937164850     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2482     Document Type: Article

References (53)

1. Poole KE, van Bezooijen RL, Loveridge N, et al., Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19 (13): 1842-4.
2. Brunkow ME, Gardner JC, Van Ness J, et al., Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68 (3): 577-89.
3. Kusu N, Laurikkala J, Imanishi M, et al., Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem. 2003; 278 (26): 24113-7.
4. Winkler DG, Sutherland MK, Geoghegan JC, et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22 (23): 6267-76.
5. van Bezooijen RL, Roelen BA, Visser A, et al., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199 (6): 805-14.
6. van Bezooijen RL, Svensson JP, Eefting D, et al., Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22 (1): 19-28.
7. Semenov M, Tamai K, He X,. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280 (29): 26770-5.
8. Leupin O, Piters E, Halleux C, et al., Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011; 286 (22): 19489-500.
9. Ke HZ, Richards WG, Li X, Ominsky MS., Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33 (5): 747-83.
10. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26 (1): 19-26.
11. Ominsky MS, Niu QT, Li C, Li X, Ke HZ,. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014; 29 (6): 1424-30.
12. Ominsky MS, Vlasseros F, Jolette J, et al., Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25 (5): 948-59.
13. Espina V, Heiby M, Pierobon M, Liotta LA., Laser capture microdissection technology. Expert Rev Mol Diagn. 2007; 7 (5): 647-57.
14. Applied Biosystems. Applied Biosystems User Bulletin No. 2 (P/N 4303859) [Internet]. Carlsbad, MA, USA: Applied Biosystems; 1997. Available at: http://www3.appliedbiosystems.com/cms/groups/mcb-support/documents/generaldocuments/cms-040980.pdf Accessed August 25, 2014.
15. Nusse R. The Wnt homepage: Wnt target genes [Internet]. Stanford, CA, USA: The Nusse Laboratory; 2014. Available at: http://web.stanford.edu/group/nusselab/cgi-bin/wnt/target-genes Accessed August 25, 2014.
16. Logan CY, Nusse R., The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781-810.
17. Grigoryan T, Wend P, Klaus A, Birchmeier W., Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev. 2008; 22 (17): 2308-41.
18. van Bezooijen RL, Bronckers AL, Gortzak RA, et al., Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009; 88 (6): 569-74.
19. Paic F, Igwe JC, Nori R, et al., Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009; 45 (4): 682-92.
20. Qing H, Ardeshirpour L, Pajevic PD, et al., Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012; 27 (5): 1018-29.
21. Kamioka H, Honjo T, Takano-Yamamoto T., A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone. 2001; 28 (2): 145-9.
22. Dallas SL, Bonewald LF., Dynamics of the transition from osteoblast to osteocyte. Ann NY Acad Sci. 2010; 1192: 437-43.
23. Wang K, Keightley A, Veno P, Dusevich V, Tiede-Lewis L, Bonewald L, Dallas S., Osteocyte microvesicles in cell-cell communication in bone. J Bone Miner Res. 2014; 29 (Suppl 1). Available at http://www.asbmr.org/education/2014-abstracts. Accessed October 16, 2014.
24. Waldman T, Kinzler KW, Vogelstein B., p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995; 55 (22): 5187-90.
25. Madden SL, Galella EA, Riley D, Bertelsen AH, Beaudry GA., Induction of cell growth regulatory genes by p53. Cancer Res. 1996; 56 (23): 5384-90.
26. Dalvai M, Mondesert O, Bourdon JC, Ducommun B, Dozier C., Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Oncogene. 2011; 30 (19): 2282-8.
27. Lee DF, Su J, Ang YS, et al., Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell. 2012; 11 (2): 179-94.
28. Gjoerup OV, Wu J, Chandler-Militello D, et al., Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci USA. 2007; 104 (20): 8334-9.
29. Junk DJ, Cipriano R, Stampfer M, Jackson MW., Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells. PLoS One. 2013; 8 (2): e53776.
30. Lengner CJ, Steinman HA, Gagnon J, et al., Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol. 2006; 172 (6): 909-21.
31. Wang X, Kua HY, Hu Y, et al., p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol. 2006; 172 (1): 115-25.
32. Manilay JO, Zouali M., Tight relationships between B lymphocytes and the skeletal system. Trends Mol Med. 2014; 20 (7): 405-12.
33. Tamura M, Sato MM, Nashimoto M., Regulation of CXCL12 expression by canonical Wnt signaling in bone marrow stromal cells. Int J Biochem Cell Biol. 2011; 43 (5): 760-7.
34. Liu C, Weng Y, Yuan T, et al., CXCL12/CXCR4 signal axis plays an important role in mediating bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells. Int J Med Sci. 2013; 10 (9): 1181-92.
35. Cain CJ, Rueda R, McLelland B, Collette NM, Loots GG, Manilay JO., Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res. 2012; 27 (7): 1451-61.
36. Li X, Liu H, Qin L, et al., Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007; 282 (45): 33086-97.
37. Yu EW, Kumbhani R, Siwila-Sackman E, et al., Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women. J Bone Miner Res. 2014; 29 (6): 1380-6.
38. Kedlaya R, Veera S, Horan DJ, et al., Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med. 2013; 5 (211): 211ra158.
39. Tu X, Rhee Y, Condon KW, et al., Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012; 50 (1): 209-17.
40. Bonewald LF, Johnson ML., Osteocytes, mechanosensing and Wnt signaling. Bone. 2008; 42 (4): 606-15.
41. Mantila Roosa SM, Liu Y, Turner CH., Gene expression patterns in bone following mechanical loading. J Bone Miner Res. 2011; 26 (1): 100-12.
42. Case N, Xie Z, Sen B, et al., Mechanical activation of beta-catenin regulates phenotype in adult murine marrow-derived mesenchymal stem cells. J Orthop Res. 2010; 28 (11): 1531-8.
43. Farge E., Mechanical induction of Twist in the Drosophila foregut/stomodeal primordium. Curr Biol. 2003; 13 (16): 1365-77.
44. Karamichos D, Skinner J, Brown R, Mudera V., Matrix stiffness and serum concentration effects matrix remodelling and ECM regulatory genes of human bone marrow stem cells. J Tissue Eng Regen Med. 2008; 2 (2-3): 97-105.
45. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, et al., Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006; 281 (42): 31720-8.
46. Li X, Ominsky MS, Warmington KS, et al., Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24 (4): 578-88.
47. Glass DA, 2nd, Bialek P, Ahn JD, et al., Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8 (5): 751-64
48. Samee N, Geoffroy V, Marty C, et al., Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol. 2008; 173 (3): 773-80.
49. Yoo HI, Kang JH, Yang SY, et al., Differential expression of cxcl-14 during eruptive movement of rat molar germs. J Exp Zool B Mol Dev Evol. 2011; 316 (6): 418-26.
50. Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P., Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone. 2005; 36 (5): 840-53.
51. Maeda A OM, Kilts T, Li L, Holmbeck K, Robey P, Young M., WISP1/CCN4 controls bone mass by uncoupling osteoblast and osteoclast function potentially by regulation of Wnt signaling. J Bone Miner Res. 2014; 29 (Supp l). Available at http://www.asbmr.org/education/2014-abstracts Accessed October 16, 2014.
52. Canales RD, Luo Y, Willey JC, et al., Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol. 2006; 24 (9): 1115-22.
53. McClung MR, Grauer A, Boonen S, et al., Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370 (5): 412-420